Filing Flows › ENvue Medical (FEED) › Q3 2025
ENvue Medical (FEED) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
ENvue Medical (FEED) reported revenue of $722K for the third quarter 2025 (Q3 2025), +92% from a year earlier and +46% from the quarter before. Operating margin was -311.2%, net earnings $510K (70.6% of revenue).
ENvue Medical, Q3 2025: revenue $722K (+92% year over year), operating margin -311.2%, net earnings $510K, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $722K | +46% | +92% |
| Operating profit | −$2.2M | — | — |
| Net earnings | $510K | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $722K in Q3 2025, up 92% year over year and up 46% from the previous quarter. Nano Vibronix was the largest line at 51% of revenue. Nano Vibronix declined 1%.
Gross margin was 26.2%, down 9.2 points from a year earlier. Operating costs exceeded revenue by $2.2M, an operating margin of -311.2%. Operating expenses grew 121% against revenue growth of 92%. The fastest-growing cost line was Sales & marketing (+349%). Net earnings were $510K. The effective tax rate was 6.4%. Non-operating items added $2.8M, 512% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.0M. Non-cash charges added back $257K of depreciation and amortization. Working capital and other items used $2.7M. Capital expenditures of $28K exceeded it, leaving free cash flow of −$2.0M.
Questions
What was ENvue Medical's revenue in the third quarter 2025?
ENvue Medical (FEED) reported revenue of $722K for the third quarter 2025 (Q3 2025), +92% from a year earlier and +46% from the quarter before.
Was ENvue Medical profitable in the third quarter 2025?
Operating loss was $2.2M (-311.2% of revenue) and net earnings $510K.
Source: ENvue Medical 10-Q on SEC EDGAR.